EQUITY
PURCHASE AGREEMENT


THIS
EQUITY PURCHASE AGREEMENT (this “Agreement”) is entered into as of July 14, 2020 (the “Execution
Date”), by and between NuGenerex Immuno-Oncology Inc., a Delaware corporation (the “Company”), and
Oasis Capital, LLC, a Puerto Rico limited liability company (the “Investor”).


RECITALS


WHEREAS,
the parties desire that, upon the terms and subject to the conditions contained herein, the Company shall issue and sell to the
Investor, from time to time as provided herein, and the Investor shall purchase from the Company up to Fifty Million Dollars ($50,000,000.00)
of the Company’s Common Stock (as defined below);


NOW,
THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the Company and the Investor hereby agree as follows:


Article
I

CERTAIN DEFINITIONS


Section
1.1               RECITALS.
The parties acknowledge and agree that the recitals set forth above are true and correct and are hereby incorporated in and made
a part of this Agreement. 


Section
1.2               DEFINED
TERMS. As used in this Agreement, the following terms shall have the following meanings specified or indicated (such meanings
to be equally applicable to both the singular and plural forms of the terms defined):


“Agreement”
shall have the meaning specified in the preamble hereof.


“Available
Amount” means, initially, the Maximum Commitment Amount, which amount shall be reduced by the Investment Amount following
each successful Closing, each time the Investor purchases shares of Common Stock pursuant to an Option 1 Put or Option 2 Put.


“Average
Daily Trading Volume” shall mean the average trading volume of the Company’s Common Stock in the ten (10) Trading
Days immediately preceding the respective Put Date.


“Bankruptcy
Law” means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors.


“Claim
Notice” shall have the meaning specified in Section 9.3(a).


“Clearing
Costs” shall mean all of the Investor’s broker and Transfer Agent fees.


“Clearing
Date” shall be the date on which the Investor receives the Put Shares as DWAC Shares in its brokerage account.


“Closing”
shall mean one of the closings of a purchase and sale of shares of Common Stock pursuant to Section 2.3.


“Closing
Certificate” shall mean the closing “Officer’s Certificate” of the Company in the form of Exhibit
B hereto.


“Closing
Date” shall mean the date of any Closing hereunder.


"Commitment
Period” shall mean the period commencing on the Execution Date, and ending on the earlier of (i) the date on which the
Investor shall have purchased Put Shares pursuant to this Agreement equal to the Maximum Commitment Amount, (ii) July ___, 2023,
or (iii) written notice of termination by the Company to the Investor (which shall not occur at any time that the Investor holds
any of the Put Shares).


“Commitment
Shares” means 300,000 shares of Common Stock issued by the Company to the Investor pursuant to Section 6.5 having
an aggregate market value, based on the estimated initial public offering price of $5.00/share, of $1,500,000.00, and adjusted
for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction.


“Common
Stock” shall mean the Company’s common stock, $0.001 par value per share, and any shares of any other class of
common stock whether now or hereafter authorized, having the right to participate in the distribution of dividends (as and when
declared) and assets (upon liquidation of the Company).


“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock.


“Company”
shall have the meaning specified in the preamble to this Agreement.


“Confidential
Information” means any information disclosed by either party to this Agreement, or their affiliates, agents or representatives,
to the other party to this Agreement, either directly or indirectly, in writing, orally or by inspection of tangible objects (including,
without limitation, documents, formulae, business information, trade secrets, technology, strategies. prototypes, samples, plant
and equipment), which may or may not be designated as “Confidential,” “Proprietary” or some similar designation.
Information communicated orally shall be considered Confidential Information. Confidential Information may also include information
disclosed by third parties. Confidential Information shall not, however, include any information which (i) was publicly known
and made generally available in the public domain prior to the time of disclosure by the disclosing party; (ii) becomes publicly
known and made generally available after disclosure by the disclosing party to the receiving party through no fault, action or
inaction of the receiving party; (iii) is already in the possession of the receiving party at the time of disclosure by the disclosing
party as shown by the receiving party’s files and records immediately prior to the time of disclosure; (iv) is obtained
by the receiving party from a third party without a breach of such third party’s obligations of confidentiality; (v) is
independently developed by the receiving party without use of or reference to the disclosing party’s Confidential Information,
as shown by documents and other competent evidence in the receiving party’s possession; or (vi) is required by law to be
disclosed by the receiving party, provided that the receiving party gives the disclosing party prompt written notice of such requirement
prior to such disclosure and assistance in obtaining an order protecting the information from public disclosure.


“Current
Report” shall have the meaning set forth in Section 6.4.


“Custodian”
means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.


“Damages”
shall mean any loss, claim, damage, liability, cost and expense (including, without limitation, reasonable attorneys’ fees
and disbursements and costs and expenses of expert witnesses and investigation).


“Dispute
Period” shall have the meaning specified in Section 9.3(a).


“Disqualification
Event” shall have the meaning specified in Section 4.27.


“DTC”
shall mean The Depository Trust Company, or any successor performing substantially the same function for the Company.


“DTC/FAST
Program” shall mean the DTC’s Fast Automated Securities Transfer Program.


“DWAC”
shall mean Deposit Withdrawal at Custodian as defined by the DTC.


“DWAC
Eligible” shall mean that (a) the Common Stock is eligible at DTC for full services pursuant to DTC’s operational
arrangements, including, without limitation, transfer through DTC’s DWAC system, (b) the Company has been approved (without
revocation) by the DTC’s underwriting department, (c) the Transfer Agent is approved as an agent in the DTC/FAST Program,
(d) the Commitment Shares or Put Shares, as applicable, are otherwise eligible for delivery via DWAC, and (e) the Transfer Agent
does not have a policy prohibiting or limiting delivery of the Put Shares or Commitment Shares, as applicable, via DWAC.


“DWAC
Shares” means shares of Common Stock that are (i) issued in electronic form, (ii) freely tradable and transferable and
without restriction on resale and (iii) timely credited by the Company to the Investor’s or its designee’s specified
DWAC account with DTC under the DTC/FAST Program, or any similar program hereafter adopted by DTC performing substantially the
same function.


“Environmental
Laws” shall have the meaning set forth in Section 4.14.


“Exchange
Act” shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.


“Execution
Date” shall have the meaning set forth in the preamble to this Agreement.


“FINRA”
shall mean the Financial Industry Regulatory Authority, Inc.


“Floor
Price” shall mean $1 per share, which shall be adjusted for any reorganization, recapitalization, non-cash dividend,
stock split or other similar transaction and, effective upon the consummation of any such reorganization, recapitalization, non-cash
dividend, stock split or other similar transaction, the Floor Price shall mean the lower of (i) the adjusted price and (ii) $1.


“Indemnified
Party” shall have the meaning specified in Section 9.2.


“Indemnifying
Party” shall have the meaning specified in Section 9.2.


“Indemnity
Notice” shall have the meaning specified in Section 9.3(b).


“Intellectual
Property” shall mean all trademarks, trademark applications, trade names, service marks, service mark registrations,
service names, patents, patent applications, patent rights, copyrights, inventions, licenses, approvals, government authorizations,
trade secrets or other intellectual property rights.


“Investment
Amount” shall mean the dollar value equal to the amount of Put Shares referenced in the Put Notice multiplied by the
Option 1 Purchase Price or Option 2 Purchase Price (as applicable) minus the Clearing Costs.


“Investor”
shall have the meaning specified in the preamble to this Agreement.


“Issuer
Covered Person” shall have the meaning specified in Section 4.27.


“Lien”
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or any other restriction.


“Material
Adverse Effect” shall mean any effect on the business, operations, properties, or financial condition of the Company
and/or the Subsidiaries that is material and adverse to the Company and/or the Subsidiaries and/or any condition, circumstance,
or situation that would prohibit or otherwise materially interfere with the ability of the Company and/or the Subsidiaries to
enter into and/or perform its obligations under any Transaction Document.


“Maximum
Commitment Amount” shall mean Fifty Million Dollars ($50,000,000.00).


“Option
1 Maximum Put Amount” shall mean:


(a)               
if, on the Put Date, the closing bid price of
the Common Stock on the Principal Market is below $6.00, then “Option 1 Maximum Put Amount” shall mean the lesser
of (i) 25,000 shares, or (ii) twenty percent (20%) of the Average Daily Trading Volume; or


(b)               
if, on the Put Date, the closing bid price of
the Common Stock on the Principal Market is $6.00 or greater but less than $7.00, then “Option 1 Maximum Put Amount”
shall mean the lesser of (i) 30,000 shares, or (ii) twenty percent (20%) of the Average Daily Trading Volume; or


(c)               
if, on the Put Date, the closing bid price of
the Common Stock on the Principal Market is $7.00 or greater, then “Option 1 Maximum Put Amount” shall mean the lesser
of (i) 40,000 shares, or (ii) twenty percent (20%) of the Average Daily Trading Volume.


“Option
1 Purchase Price” shall mean the lesser of (i) the one (1) lowest traded price of the Common Stock on the Principal
Market on the Clearing Date, or (ii) the average of the three (3) lowest closing sale prices of the Common Stock on the Principal
Market during the Option 1 Valuation Period, as reported by Bloomberg Finance L.P. or other reputable source.


“Option
1 Put” shall mean the right of the Company to require the Investor to purchase shares of Common Stock at the Option
1 Purchase Price, subject to the terms and conditions of this Agreement.


“Option
1 Valuation Period” shall mean the period of twelve (12) consecutive Trading Days immediately preceding the Clearing
Date associated with the applicable Put Notice during which the Option 1 Purchase Price of the Common Stock is valued.


“Option
2 Maximum Put Amount” shall mean the lesser of (i) such amount that equals ten percent (10%) of the daily trading volume
of the Common Stock on the Put Date, and (ii) a number of shares of Common Stock equal to (x) Five Hundred Thousand Dollars ($500,000.00)
divided by (y) the Option 2 Purchase Price.


“Option
2 Purchase Price” shall mean the lesser of (i) 92% of the one (1) lowest traded price of the Common Stock on the Principal
Market during the Option 2 Valuation Period as reported by Bloomberg Finance L.P. or other reputable source, or (ii) 92% of the
VWAP on the Clearing Date, or (iii) 92% of the closing bid price of the Common Stock on the Principal Market on the Clearing Date.


“Option
2 Put” shall mean the right of the Company to require the Investor to purchase shares of Common Stock at the Option
2 Purchase Price, subject to the terms and conditions of this Agreement.


“Option
2 Valuation Period” shall mean the period of ten (10) consecutive Trading Days immediately preceding the Put Date associated
with the applicable Put Notice during which the Option 2 Purchase Price of the Common Stock is valued.


“Person”
shall mean an individual, a corporation, a partnership, an association, a trust or other entity or organization, including a government
or political subdivision or an agency or instrumentality thereof.


“Principal
Market” shall mean the NASDAQ stock market or any other national securities exchange registered with the SEC.


“Put
Date” shall mean any Trading Day during the Commitment Period that a Put Notice is deemed delivered pursuant to Section
2.2(b).


“Put
Notice” shall mean a written notice, substantially in the form of Exhibit A hereto, addressed to the Investor
and setting forth the amount of Put Shares which the Company intends to require the Investor to purchase pursuant to the terms
of this Agreement.


“Put
Shares” shall mean all shares of Common Stock issued, or that the Company shall be entitled to issue, per any applicable
Put Notice in accordance with the terms and conditions of this Agreement.


“Registration
Rights Agreement” means that agreement in the form attached hereto as Exhibit D.


“Registration
Statement” shall have the meaning specified in Section 6.4.


“Regulation
D” shall mean Regulation D promulgated under the Securities Act.


“Rule
144” shall mean Rule 144 promulgated under the Securities Act or any similar provision then in force under the Securities
Act.


“SEC”
shall mean the United States Securities and Exchange Commission.


“SEC
Documents” shall have the meaning specified in Section 4.5.


“Securities”
means, collectively, the Put Shares and the Commitment Shares.


“Securities
Act” shall mean the Securities Act of 1933, as amended.


“Short
Sales” shall mean all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act.


“Subsidiary”
or “Subsidiaries” means any Person the Company wholly-owns or controls, or in which the Company, directly or
indirectly, owns a majority of the voting stock or similar voting interest, in each case that would be disclosable pursuant to
Item 601(b)(21) of Regulation S-K promulgated under the Securities Act.


“Third
Party Claim” shall have the meaning specified in Section 9.3(a).


“Trading
Day” shall mean a day on which the Principal Market shall be open for business.


“Transaction
Documents” shall mean this Agreement, the Registration Rights Agreement and all schedules and exhibits hereto and thereto.


“Transfer
Agent” shall mean Securities Transfer Corporation, the current transfer agent of the Company, and any successor transfer
agent of the Company.


“Transfer
Agent Instruction Letter” means the letter from the Company to the Transfer Agent which instructs the Transfer Agent
to issue the Put Shares and the Commitment Shares pursuant to the Transaction Documents, in the form of Exhibit C attached
hereto.


“VWAP”
shall mean for any date, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on such national exchange on which the Common Stock is then listed or quoted for trading as reported by Bloomberg L.P. or Quotestream,
a product of QuoteMedia, Inc. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)).


Article
II

PURCHASE AND SALE OF COMMON STOCK


Section
2.1               PUTS.
Upon the terms and conditions set forth herein (including, without limitation, the provisions of Article VII), the Company
shall have the right, but not the obligation, to direct the Investor, to process an:


(a)               
Option 1 Put by its delivery to the Investor
of a Put Notice from time to time during the Commitment Period, to purchase Put Shares, provided that notwithstanding any other
terms of this Agreement, in each instance, (i) the Investment Amount is not more than the Option 1 Maximum Put Amount for any
Option 1 Put, (ii) the aggregate Investment Amount of all Option 1 Puts and Option 2 Puts shall not exceed the Maximum Commitment
Amount; (iii) the Trading Day prior to the subject Clearing Date did not have the lowest VWAP of the Common Stock out of the prior
ten (10) consecutive Trading Days, (iv) at least two (2) Trading Days have lapsed since the most recent Clearing Date of an Option
1 Put, (v) the aggregate Investment Amount of the Option 1 Put on any particular Put Date or Clearing Date does not exceed $500,000.00,
and (vi) the lowest traded price of the Common Stock in the five (5) Trading Days immediately preceding the respective Put Date
must exceed the Floor Price; and 


(b)               
Option 2 Put by its delivery to the Investor
of a Put Notice from time to time during the Commitment Period, to purchase Put Shares, provided that notwithstanding any other
terms of this Agreement, in each instance, (i) an Option 1 Put has been previously and effectively processed and its Clearing
Date is the same day as the Put Notice for the subject Option 2 Put, (ii) the Investment Amount is not more than the Option 2
Maximum Put Amount for any Option 2 Put, (iii) the aggregate Investment Amount of all Option 1 Puts and Option 2 Puts shall not
exceed the Maximum Commitment Amount, (iv) the aggregate Investment Amount of the Option 2 Put on any particular Put Date or Clearing
Date does not exceed $500,000.00, (v) if all shares of Common Stock resulting from prior submitted Put Notices for Option 1 Puts
have been delivered, and (vi) the lowest traded price of the Common Stock in the five (5) Trading Days immediately preceding the
respective Put Date must exceed the Floor Price.


Section
2.2               MECHANICS.


(a)               
PUT NOTICE. At any time and from time
to time during the Commitment Period, except as provided in this Agreement, the Company may cause an Option 1 Put or an Option
2 Put by delivering a Put Notice to the Investor, subject to satisfaction of the conditions set forth in Section 2.1, Section
7.2 and otherwise provided in this Agreement. The Company shall deliver, or cause to be delivered, the Put Shares as DWAC
Shares to the Investor within two (2) Trading Days following the Put Date.


(b)               
DATE OF DELIVERY OF PUT NOTICE. A Put
Notice shall be deemed delivered on (i) the Trading Day it is received by e-mail by the Investor if such notice is received on
or prior to 8:30 a.m. EST or (ii) the immediately succeeding Trading Day if it is received by e-mail after 8:30 a.m. EST on a
Trading Day or at any time on a day which is not a Trading Day.


Section
2.3               CLOSINGS.



(a)               
TIMING. The Closing of an Option 1 Put
shall occur within one (1) Trading Day following the end of the respective Option 1 Valuation Period, whereby the Investor shall
deliver the Investment Amount by wire transfer of immediately available funds to an account designated by the Company. The Closing
of an Option 2 Put shall occur within one (1) Trading Day following the Clearing Date, whereby the Investor shall deliver the
Investment Amount by wire transfer of immediately available funds to an account designated by the Company. In addition, on or
prior to any such Closing, each of the Company and the Investor shall deliver to each other all documents, instruments and writings
required to be delivered or reasonably requested by either of them pursuant to this Agreement in order to implement and effect
the transactions contemplated herein.


(b)               
RETURN OF SURPLUS. If the value of the
Put Shares delivered to the Investor causes the Company to exceed the Maximum Commitment Amount, then the Investor shall return
to the Company the surplus amount of Put Shares associated with such Option 1 Put or Option 2 Put, and the Option 1 Purchase Price
or Option 2 Purchase Price with respect to such Option 1 Put or Option 2 Put shall be reduced by any Clearing Costs related to
the return of such Put Shares.


(c)               
RESALES DURING VALUATION PERIOD. The parties
acknowledge and agree that during the Option 1 Valuation Period or Option 2 Valuation Period (as applicable), the Investor may
contract for, or otherwise effect, the resale of the subject purchased Put Shares to third-parties. 


Article
III

REPRESENTATIONS AND WARRANTIES OF INVESTOR


The
Investor represents and warrants to the Company that:


Section
3.1               INTENT.
The Investor is entering into this Agreement for its own account, and the Investor has no present arrangement (whether or not
legally binding) at any time to sell the Securities to or through any Person in violation of the Securities Act or any applicable
state securities laws; provided, however, that the Investor reserves the right to dispose of the Securities at any
time in accordance with federal and state securities laws applicable to such disposition.


Section
3.2               NO
LEGAL ADVICE FROM THE COMPANY. The Investor acknowledges that it has had the opportunity to review this Agreement and the
transactions contemplated by this Agreement with its own legal counsel and investment and tax advisors. Except with respect to
the representations, warranties and covenants contained in this Agreement, the Investor is relying solely on such counsel and
advisors and not on any statements or representations of the Company or any of its representatives or agents for legal, tax or
investment advice with respect to this investment, the transactions contemplated by this Agreement or the securities laws of any
jurisdiction.


Section
3.3               ACCREDITED
INVESTOR. The Investor is an accredited investor as defined in Rule 501(a)(3) of Regulation D, and the Investor has such experience
in business and financial matters that it is capable of evaluating the merits and risks of an investment in the Securities. The
Investor acknowledges that an investment in the Securities is speculative and involves a high degree of risk.


Section
3.4               AUTHORITY.
The Investor has the requisite power and authority to enter into and perform its obligations under this Agreement and the other
Transaction Documents and to consummate the transactions contemplated hereby and thereby. The execution and delivery of this Agreement
and the other Transaction Documents and the consummation by it of the transactions contemplated hereby and thereby have been duly
authorized by all necessary action and no further consent or authorization of the Investor is required. Each Transaction Document
to which it is a party has been duly executed by the Investor, and when delivered by the Investor in accordance with the terms
hereof, will constitute the valid and binding obligation of the Investor enforceable against it in accordance with its terms,
subject to applicable bankruptcy, insolvency, or similar laws relating to, or affecting generally the enforcement of, creditors’
rights and remedies or by other equitable principles of general application.


Section
3.5               NOT
AN AFFILIATE. To the Investor’s knowledge, the Investor is not an officer, director or “affiliate” (as such
term is defined in Rule 405 of the Securities Act) of the Company.


Section
3.6               ORGANIZATION
AND STANDING. The Investor is an entity duly formed, validly existing and in good standing under the laws of the jurisdiction
of its formation with full right, limited liability company power and authority to enter into and to consummate the transactions
contemplated by this Agreement and the other Transaction Documents.


Section
3.7               ABSENCE
OF CONFLICTS. The execution and delivery of this Agreement and the other Transaction Documents, and the consummation of the
transactions contemplated hereby and thereby and compliance with the requirements hereof and thereof, will not (a) violate any
law, rule, regulation, order, writ, judgment, injunction, decree or award binding on the Investor, (b) violate any provision of
any indenture, instrument or agreement to which the Investor is a party or is subject, or by which the Investor or any of its
assets is bound, or conflict with or constitute a material default thereunder, (c) result in the creation or imposition of any
lien pursuant to the terms of any such indenture, instrument or agreement, or constitute a breach of any fiduciary duty owed by
the Investor to any third party, or (d) require the approval of any third-party (that has not been obtained) pursuant to any material
contract, instrument, agreement, relationship or legal obligation to which the Investor is subject or to which any of its assets,
operations or management may be subject.


Section
3.8               DISCLOSURE;
ACCESS TO INFORMATION. The Investor had an opportunity to review copies of the SEC Documents filed on behalf of the Company
and has had access to all publicly available information with respect to the Company; provided, however, that the Investor makes
no representation or warranty hereunder with respect to any SEC Document and is relying on the representations and warranties
of the Company in Article IV with respect to the SEC Documents.


Section
3.9               MANNER
OF SALE. At no time was the Investor presented with or solicited by or through any leaflet, public promotional meeting, television
advertisement or any other form of general solicitation or advertisement regarding the Securities.


Article
IV

REPRESENTATIONS AND WARRANTIES OF THE COMPANY


The
Company represents and warrants to the Investor that, except as set forth in the disclosure schedules hereto that as of the Execution
Date and at each Closing Date:


Section
4.1               ORGANIZATION
OF THE COMPANY. The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the
state of Delaware, with the requisite power and authority to own and use its properties and assets and to carry on its business
as currently conducted. Each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in
good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority
to own and use its properties and assets and to carry on its business as currently conducted. Each of the Company and the Subsidiaries
is not in violation or default of any of the provisions of its respective certificate or articles of incorporation, bylaws or
other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and
is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted
or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as
the case may be, could not have or reasonably be expected to result in a Material Adverse Effect and no proceeding has been instituted
in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.


Section
4.2               AUTHORITY.
The Company has the requisite corporate power and authority to enter into and perform its obligations under this Agreement and
the other Transaction Documents. The execution and delivery of this Agreement and the other Transaction Documents by the Company
and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary corporate
action and no further consent or authorization of the Company or its board of directors or stockholders is required. Each of this
Agreement and the other Transaction Documents has been duly executed and delivered by the Company and constitutes a valid and
binding obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability
may be limited by applicable bankruptcy, insolvency, or similar laws relating to, or affecting generally the enforcement of, creditors’
rights and remedies or by other equitable principles of general application.


Section
4.3               CAPITALIZATION.
As of the Execution Date, the authorized capital stock of the Company is as set forth in the SEC Documents. Except as set forth
in the SEC Documents or on Schedule 4.3, the Company has not issued any capital stock since its most recently filed periodic
report under the Exchange Act, other than pursuant to the exercise of employee stock options under the Company’s stock option
plans, the issuance of shares of Common Stock to employees pursuant to the Company’s employee stock purchase plans and pursuant
to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report
under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right
to participate in the transactions contemplated by the Transaction Documents. Except as set forth in the SEC Documents or on Schedule
4.3, and except as a result of the purchase and sale of the Securities, there are no outstanding options, warrants, scrip
rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible
into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire any shares of Common Stock,
or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue
additional shares of Common Stock or Common Stock Equivalents. The issuance and sale of the Securities will not obligate the Company
to issue shares of Common Stock or other securities to any Person (other than the Investor) and will not result in a right of
any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities. There
are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock
to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders.


Section
4.4               LISTING
AND MAINTENANCE REQUIREMENTS. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the
Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act, nor has the Company received any notification that the SEC is contemplating terminating
such registration. As of each Closing Date, the Company will not, in the twelve (12) months preceding such Closing Date, received
notice from the Principal Market to the effect that the Company is not in compliance with the listing or maintenance requirements
of such Principal Market. Except as set forth on Schedule 4.4(b), the Company is, and has no reason to believe that it
will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements.


Section
4.5               SEC
DOCUMENTS; DISCLOSURE. The Company has filed all reports, schedules, forms, statements and other documents required to be
filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for
the one (1) year preceding the Execution Date (or such shorter period as the Company was required by law or regulation to file
such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being
collectively referred to herein as the “SEC Documents”) on a timely basis or has received a valid extension
of such time of filing and has filed any such SEC Documents prior to the expiration of any such extension. As of their respective
dates, the SEC Documents complied in all material respects with the requirements of the Securities Act and the Exchange Act, as
applicable, and other federal laws, rules and regulations applicable to such SEC Documents, and none of the SEC Documents when
filed contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary
in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The financial
statements of the Company included in the SEC Documents comply as to form and substance in all material respects with applicable
accounting requirements and the published rules and regulations of the SEC or other applicable rules and regulations with respect
thereto. Such financial statements have been prepared in accordance with generally accepted accounting principles applied on a
consistent basis during the periods involved (except (a) as may be otherwise indicated in such financial statements or the notes
thereto or (b) in the case of unaudited interim statements, to the extent they may not include footnotes or may be condensed or
summary statements) and fairly present in all material respects the financial position of the Company as of the dates thereof
and the results of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal,
immaterial, year-end audit adjustments). There is no transaction, arrangement, or other relationship between the Company and an
unconsolidated or other off balance sheet entity that is not disclosed by the Company in its financial statements or otherwise
that would be reasonably likely to have a Material Adverse Effect. Except with respect to the material terms and conditions of
the transactions contemplated by the Transaction Documents, the Company confirms that neither it nor any other Person acting on
its behalf has provided the Investor or its agents or counsel with any information that it believes constitutes or might constitute
material, non-public information. The Company understands and confirms that the Investor will rely on the foregoing representation
in effecting transactions in securities of the Company.


Section
4.6               VALID
ISSUANCES. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction
Documents, will be validly issued, fully paid, and non-assessable, free and clear of all Liens imposed by the Company, other than
restrictions on transfer provided for in the Transaction Documents and under the Securities Act.


Section
4.7               NO
CONFLICTS. The execution, delivery and performance of this Agreement and the other Transaction Documents by the Company, and
the consummation by the Company of the transactions contemplated hereby and thereby, including, without limitation, the issuance
of the Put Shares and the Commitment Shares, do not and will not: (a) result in a violation of the Company’s or any Subsidiary’s
certificate or articles of incorporation, by-laws or other organizational or charter documents, (b) conflict with, or constitute
a material default (or an event that with notice or lapse of time or both would become a material default) under, result in the
creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination,
amendment, acceleration or cancellation of, any agreement, indenture, instrument or any “lock-up” or similar provision
of any underwriting or similar agreement to which the Company or any Subsidiary is a party, or (c) result in a violation of any
federal, state or local law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations)
applicable to the Company or any Subsidiary or by which any property or asset of the Company or any Subsidiary is bound or affected
(except for such conflicts, defaults, terminations, amendments, accelerations, cancellations and violations as would not, individually
or in the aggregate, have a Material Adverse Effect), nor is the Company otherwise in violation of, conflict with or in default
under any of the foregoing. The business of the Company is not being conducted in violation of any law, ordinance or regulation
of any governmental entity, except for possible violations that either singly or in the aggregate do not and will not have a Material
Adverse Effect. The Company is not required under federal, state or local law, rule or regulation to obtain any consent, authorization
or order of, or make any filing or registration with, any court or governmental agency in order for it to execute, deliver or
perform any of its obligations under this Agreement or the other Transaction Documents (other than any SEC, FINRA or state securities
filings that may be required to be made by the Company in connection with the issuance of the Commitment Shares or subsequent
to any Closing or any registration statement that may be filed pursuant hereto); provided that, for purposes of the representation
made in this sentence, the Company is assuming and relying upon the accuracy of the relevant representations and agreements of
Investor herein.


Section
4.8               NO
MATERIAL ADVERSE CHANGE. No event has occurred that would have a Material Adverse Effect on the Company or any Subsidiary
that has not been disclosed in subsequent SEC filings.


Section
4.9               LITIGATION
AND OTHER PROCEEDINGS. Except as set forth on Schedule 4.9, there are no actions, suits, investigations, inquiries
or proceedings pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any
of their respective properties, nor has the Company received any written or oral notice of any such action, suit, proceeding,
inquiry or investigation, which would have a Material Adverse Effect or would require disclosure under the Securities Act or the
Exchange Act. No judgment, order, writ, injunction or decree or award has been issued by or, to the knowledge of the Company,
requested of any court, arbitrator or governmental agency which would have a Material Adverse Effect. There has not been, and
to the knowledge of the Company, there is not pending or contemplated, any investigation by the SEC involving the Company, any
Subsidiary, or any current or former director or officer of the Company or any Subsidiary.


Section
4.10            REGISTRATION
RIGHTS. Except as set forth on Schedule 4.10, no Person (other than the Investor) has any right to cause the Company
to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.


Section
4.11            INVESTOR’S
STATUS. The Company acknowledges and agrees that the Investor is acting solely in the capacity of arm’s length purchaser
with respect to the Transaction Documents and the transactions contemplated hereby and thereby. The Company further acknowledges
that the Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to
the Transaction Documents and the transactions contemplated hereby and thereby and any advice given by the Investor or any of
its representatives or agents in connection with the Transaction Documents and the transactions contemplated hereby and thereby
is merely incidental to the Investor’s purchase of the Securities. The Company further represents to the Investor that the
Company’s decision to enter into the Transaction Documents has been based solely on the independent evaluation by the Company
and its representatives and advisors.


Section
4.12            NO
GENERAL SOLICITATION; NO INTEGRATED OFFERING. Neither the Company, any Subsidiary, nor any of their respective affiliates,
nor any Person acting on their behalf, has engaged in any form of general solicitation or general advertising (within the meaning
of Regulation D under the Securities Act) in connection with the offer or sale of the Securities. Neither the Company, any Subsidiary,
nor any of their respective affiliates, nor any Person acting on their behalf has, directly or indirectly, made any offers or
sales of any security or solicited any offers to buy any security, under circumstances that would require registration of the
offer and sale of any of the Securities under the Securities Act, whether through integration with prior offerings or otherwise,.
The issuance and sale of the Securities hereunder will not contravene the rules and regulations of the Principal Market.


Section
4.13            INTELLECTUAL
PROPERTY RIGHTS. The Company and each Subsidiary own or possess adequate rights or licenses to use all material trademarks,
trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses,
approvals, governmental authorizations, trade secrets and rights necessary to conduct their respective businesses as now conducted.
None of the Company’s, nor any Subsidiary’s Intellectual Property has expired or terminated, or, by the terms and
conditions thereof, could expire or terminate within three years from the date of this Agreement if such expiration or termination
could reasonably be expected to have a Material Adverse Effect. The Company does not have any knowledge of any infringement by
the Company and/or any Subsidiary of any material Intellectual Property of others, or of any such development of similar or identical
trade secrets or technical information by others, and there is no claim, action or proceeding being made or brought against, or
to the Company’s knowledge, being threatened against, the Company and/or any Subsidiary regarding the infringement of any
Intellectual Property, which could reasonably be expected to have a Material Adverse Effect.


Section
4.14            ENVIRONMENTAL
LAWS. To the Company’s knowledge, the Company and each Subsidiary (i) is in compliance with any and all applicable foreign,
federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous
or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”), (ii) has received all permits,
licenses or other approvals required of it under applicable Environmental Laws to conduct its respective businesses and (iii)
is in compliance with all terms and conditions of any such permit, license or approval, except where, in each of the three foregoing
clauses, the failure to so comply could not reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect.


Section
4.15            TITLE.
Except as disclosed in the SEC Documents, the Company and each Subsidiary has good and marketable title in fee simple to all real
property owned by it and good and marketable title in all personal property owned by it that is material to the business of the
Company and each Subsidiary, in each case free and clear of all Liens and, except for Liens as do not materially affect the value
of such property and do not materially interfere with the use made and proposed to be made of such property by the Company or
any Subsidiary and Liens for the payment of federal, state or other taxes, the payment of which is neither delinquent nor subject
to penalties. Any real property and facilities held under lease by the Company or any Subsidiary is held under valid, subsisting
and enforceable leases with which the Company is in compliance with such exceptions as are not material and do not interfere with
the use made and proposed to be made of such property and buildings by the Company or any Subsidiary.


Section
4.16            INSURANCE.
The Company and each Subsidiary is insured by insurers of recognized financial responsibility against such losses and risks and
in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company and each
Subsidiary is engaged. Neither the Company, nor any Subsidiary has been refused any insurance coverage sought or applied for,
and the Company has no reason to believe that it or any Subsidiary will not be able to renew its existing insurance coverage as
and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business
at a cost that would not materially and adversely affect the condition, financial or otherwise, or the earnings, business or operations
of the Company, taken as a whole.


Section
4.17            REGULATORY
PERMITS. The Company and each Subsidiary possesses all material certificates, authorizations and permits issued by the appropriate
federal, state or foreign regulatory authorities necessary to conduct its businesses, and neither the Company, nor any Subsidiary
has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit.


Section
4.18            TAX
STATUS. The Company and each Subsidiary has made or filed all federal and state income and all other material tax returns,
reports and declarations required by any jurisdiction to which it is subject (unless and only to the extent that the Company has
set aside on its books provisions reasonably adequate for the payment of all unpaid and unreported taxes) and has paid all taxes
and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports
and declarations, except those being contested in good faith and has set aside on its books provision reasonably adequate for
the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are
no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the
Company know of no basis for any such claim.


Section
4.19            TRANSACTIONS
WITH AFFILIATES. Except as set forth in the SEC Documents, none of the officers or directors of the Company or any Subsidiary,
and to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction
with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement
or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or
from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any
entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or
partner, in each case in excess of the lesser of (i) $120,000 or (ii) one percent of the average of the Company’s total
assets at year end for the last two completed fiscal years, other than for (i) payment of salary or consulting fees for services
rendered, (ii) reimbursement for expenses incurred on behalf of the Company or any Subsidiary and (iii) other employee benefits,
including stock option agreements under any stock option plan of the Company.


Section
4.20            APPLICATION
OF TAKEOVER PROTECTIONS. The Company and its board of directors have taken or will take prior to the Execution Date all necessary
action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any
distribution under a rights agreement) or other similar anti-takeover provision under the articles of incorporation or the laws
of the state of its incorporation which is or could become applicable to the Investor as a result of the transactions contemplated
by this Agreement, including, without limitation, the Company’s issuance of the Securities and the Investor’s ownership
of the Securities.


Section
4.21            FOREIGN
CORRUPT PRACTICES. Neither the Company, any Subsidiary, nor to the knowledge of the Company, any agent or other Person acting
on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts,
entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to
foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any Person acting on
its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision
of the Foreign Corrupt Practices Act of 1977, as amended.


Section
4.22            SARBANES-OXLEY.
The Company is in compliance with all provisions of the Sarbanes-Oxley Act of 2002, as amended, which are applicable to it.


Section
4.23            CERTAIN
FEES. No brokerage or finder’s fees or commissions are or will be payable by the Company to any broker, financial advisor
or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated
by the Transaction Documents. The Investor shall have no obligation with respect to any fees or with respect to any claims made
by or on behalf of any Persons for fees of a type contemplated in this Section 4.23 that may be due in connection with
the transactions contemplated by the Transaction Documents.


Section
4.24            INVESTMENT
COMPANY. The Company is not an “investment company” within the meaning of the Investment Company Act of 1940,
as amended.


Section
4.25            ACCOUNTANTS.
The Company’s accountants are set forth in the SEC Documents and, to the knowledge of the Company, such accountants are
an independent registered public accounting firm as required by the Securities Act.


Section
4.26            NO
MARKET MANIPULATION. Neither the Company, nor any Subsidiary has, and to its knowledge no Person acting on either of their
behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation
of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased,
or, paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any
compensation for soliciting another to purchase any other securities of the Company.


Section
4.27            NO
DISQUALIFICATION EVENTS. None of the Company, any Subsidiary, any of their predecessors, any affiliated issuer, any director,
executive officer, other officer of the Company or any Subsidiary participating in the offering contemplated hereby, any beneficial
owner of 20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, nor
any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the
time of sale (each, an “Issuer Covered Person”) is subject to any of the “Bad Actor” disqualifications
described in Rule 506(d)(1) under the Securities Act (a “Disqualification Event”), except for a Disqualification
Event covered by Rule 506(d)(2) or (d)(3) under the Securities Act. The Company has exercised reasonable care to determine whether
any Issuer Covered Person is subject to a Disqualification Event.


Section
4.28            MONEY
LAUNDERING. The Company and each Subsidiary is in compliance with, and has not previously violated, the USA PATRIOT ACT of
2001 and all other applicable U.S. and non-U.S. anti-money laundering laws and regulations, including, but not limited to, the
laws, regulations and Executive Orders and sanctions programs administered by the U.S. Office of Foreign Assets Control, including,
but not limited, to (i) Executive Order 13224 of September 23, 2001 entitled, “Blocking Property and Prohibiting Transactions
With Persons Who Commit, Threaten to Commit, or Support Terrorism” (66 Fed. Reg. 49079 (2001)); and (ii) any regulations
contained in 31 CFR, Subtitle B, Chapter V.


Section
4.29            ILLEGAL
OR UNAUTHORIZED PAYMENTS; POLITICAL CONTRIBUTIONS. Neither the Company, nor any Subsidiary has, nor, to the best of the Company’s
knowledge (after reasonable inquiry of its officers and directors), any of the officers, directors, employees, agents or other
representatives of the Company, any Subsidiary or any other business entity or enterprise with which the Company is or has been
affiliated or associated, has, directly or indirectly, made or authorized any payment, contribution or gift of money, property,
or services, whether or not in contravention of applicable law, (a) as a kickback or bribe to any Person or (b) to any political
organization, or the holder of or any aspirant to any elective or appointive public office except for personal political contributions
not involving the direct or indirect use of funds of the Company.


Section
4.30            SHELL
COMPANY STATUS. The Company is not currently an issuer identified in Rule 144(i)(1)(i) under the Securities Act, is subject
to the reporting requirements of Section 13 or 15(d) of the Exchange Act, has filed all reports and other materials required to
be filed by Section 13 or 15(d) of the Exchange Act, as applicable during the preceding 12 months, and, as of a date at least
one year prior to the Execution Date, has filed current “Form 10 information” with the SEC (as defined in Rule 144(i)(3)
of the Securities Act) reflecting its status as an entity that is no longer an issuer described in Rule 144(i)(1)(i) of the Securities
Act.


Section
4.31            ABSENCE
OF SCHEDULES. In the event that on the Execution Date, the Company does not deliver any disclosure schedule contemplated by
this Agreement, the Company hereby acknowledges and agrees that (i) each such undelivered disclosure schedule shall be deemed
to read as follows: “Nothing to Disclose”, and (ii) the Investor has not otherwise waived delivery of such disclosure
schedule. 


Article
V

COVENANTS OF INVESTOR


Section
5.1               COMPLIANCE
WITH LAW; TRADING IN SECURITIES. The Investor’s trading activities with respect to shares of Common Stock will be in
compliance with all applicable state and federal securities laws and regulations and the rules and regulations of FINRA and the
Principal Market.


Section
5.2               SHORT
SALES AND CONFIDENTIALITY. Neither the Investor, nor any affiliate of the Investor acting on its behalf or pursuant to any
understanding with it, will execute any Short Sales during the period from the Execution Date to the end of the Commitment Period.
For the purposes hereof, and in accordance with Regulation SHO, the sale after delivery of a Put Notice of such number of shares
of Common Stock reasonably expected to be purchased under a Put Notice shall not be deemed a Short Sale. The Investor shall, until
such time as the transactions contemplated by this Agreement are publicly disclosed by the Company in accordance with the terms
of this Agreement, maintain the confidentiality of the existence and terms of this transaction and the information included in
the Transaction Documents. The Investor agrees not to disclose any Confidential Information of the Company to any third party,
except for attorneys, accountants, advisors who have a need to know such Confidential Information and are bound by confidentiality,
and shall not use any Confidential Information for any purpose other than in connection with, or in furtherance of, the transactions
contemplated hereby. The Investor acknowledges that the Confidential Information of the Company shall remain the property of the
Company and agrees that it shall take all reasonable measures to protect the secrecy of any Confidential Information disclosed
by the Company.


Article
VI

COVENANTS OF THE COMPANY


Section
6.1               REMOVED
AND RESERVED. 


Section
6.2               LISTING
OF COMMON STOCK. As long as the Investor is the owner of any Put Shares, the Company shall use its commercially reasonable
efforts to continue the listing and trading of the Common Stock on the Principal Market (including, without limitation, maintaining
sufficient net tangible assets) and will comply in all respects with the Company’s reporting, filing and other obligations
under the bylaws or rules of FINRA and the Principal Market. The Company shall not take any action that would reasonably be expected
to result in the delisting or suspension of the Common Stock on the Principal Market. The Company shall promptly, and in no event
later than the following Trading Day, provide to the Investor copies of any notices it receives from any Person regarding the
continued eligibility of the Common Stock for listing on the Principal Market. The Company shall pay all fees and expenses in
connection with satisfying its obligations under this Section 6.2). The Company shall take all action necessary to ensure
that its Common Stock can be transferred electronically as DWAC Shares.


Section
6.3               OTHER
EQUITY LINES. So long as this Agreement remains in effect, the Company covenants and agrees that it will not, without the
prior written consent of the Investor, enter into any other equity line of credit agreement with any other party, without the
Investor’s prior written consent, which consent may be granted or withheld in the Investor’s sole and absolute discretion.



Section
6.4               FILING
OF CURRENT REPORT AND REGISTRATION STATEMENT. The Company agrees that it shall file a Current Report on Form 8-K, including
the Transaction Documents as exhibits thereto, with the SEC within the time required by the Exchange Act, relating to the transactions
contemplated by, and describing the material terms and conditions of, the Transaction Documents (the “Current Report”).
The Company shall permit the Investor to review and comment upon the final pre-filing draft version of the Current Report at least
two (2) Trading Days prior to its filing with the SEC, and the Company shall give reasonable consideration to all such comments.
The Investor shall use its reasonable best efforts to comment upon the final pre-filing draft version of the Current Report within
one (1) Trading Day from the date the Investor receives it from the Company. Pursuant to the terms of the Registration Rights
Agreement, the Company shall also file with the SEC, on or before the 30th (30th) day following the Execution Date, a new registration
statement on Form S-1 (the “Registration Statement”) covering only the resale of the Put Shares and Commitment
Shares.


Section
6.5               ISSUANCE
OF COMMITMENT SHARES. In consideration for the Investor’s execution and delivery of, and performance under this Agreement,
the Company shall cause the Transfer Agent to issue the Commitment Shares to the Investor on the Execution Date. For the avoidance
of doubt, all of the Commitment Shares shall be fully earned as of the Execution Date, and the issuance of the Commitment Shares
is not contingent upon any other event or condition, including, without limitation, the effectiveness of the Registration Statement
or the Company’s submission of a Put Notice to the Investor and irrespective of any termination of this Agreement. The Company
shall register all Commitment Shares with any registration statement filed which registers any Put Shares. 


Section
6.6               DUE
DILIGENCE; CONFIDENTIALITY; NON-PUBLIC INFORMATION. The Investor shall have the right, from time to time as the Investor may
reasonably deem appropriate, to perform reasonable due diligence on the Company during normal business hours. The Company, each
Subsidiary and their respective officers and employees shall provide information and reasonably cooperate with the Investor in
connection with any reasonable request by the Investor related to the Investor’s due diligence of the Company. The Company
confirms that neither it nor any other Person acting on its behalf shall provide the Investor or its agents or counsel with any
information that constitutes or might constitute material, non-public information, unless a simultaneous public announcement thereof
is made by the Company in the manner contemplated by Regulation FD. In the event of a breach of the foregoing covenant by the
Company or any Person acting on its behalf (as determined in the reasonable good faith judgment of the Investor), in addition
to any other remedy provided herein or in the other Transaction Documents, the Investor shall have the right to make a public
disclosure, in the form of a press release, public advertisement or otherwise, of such material, non-public information without
the prior approval by the Company; provided the Investor shall have first provided notice to the Company that it believes it has
received information that constitutes material, non-public information, and the Company shall have had at least twenty-four (24)
hours to publicly disclose such material, non-public information prior to any such disclosure by the Investor, and the Company
shall have failed to publicly disclose such material, non-public information within such time period. The Investor shall not have
any liability to the Company, any Subsidiary, or any of their respective directors, officers, employees, stockholders, affiliates
or agents, for any such disclosure. The Company understands and confirms that the Investor shall be relying on the foregoing covenants
in effecting transactions in securities of the Company.


Section
6.7               PURCHASE
RECORDS. The Company shall maintain records showing the Available Amount at any given time and the date, Investment Amount
and Put Shares for each Option 1 Put or Option 2 Put, contained in the applicable Put Notice.


Section
6.8               TAXES.
The Company shall pay any and all transfer, stamp or similar taxes that may be payable with respect to the issuance and delivery
of any shares of Common Stock to the Investor made under this Agreement.


Section
6.9               USE
OF PROCEEDS. The Company will use the net proceeds from the offering of Put Shares hereunder in the manner described in the
Registration Statement or the SEC Documents.


Section
6.10            OTHER
TRANSACTIONS. The Company shall not enter into, announce or recommend to its stockholders any agreement, plan, arrangement
or transaction in or of which the terms thereof would restrict, materially delay, conflict with or impair the ability or right
of the Company to perform its obligations under the Transaction Documents, including, without limitation, the obligation of the
Company to deliver the Put Shares and the Commitment Shares to the Investor in accordance with the terms of the Transaction Documents.


Section
6.11            INTEGRATION.
In any case subject to the terms of the Registration Rights Agreement, from and after the Execution Date, neither the Company,
nor or any of its Subsidiaries or affiliates will, and the Company shall use its reasonable best efforts to ensure that no Person
acting on their behalf will, directly or indirectly, make any offers or sales of any security or solicit any offers to buy any
security, under circumstances that would require registration of the offer and sale of any of the Securities under the Securities
Act.


Section
6.12            [Intentionally
Omitted.]


Section
6.13            TRANSACTION
DOCUMENTS. On the Execution Date, the Company shall deliver to the Investor executed copies of all of the Transaction Documents.



Article
VII

CONDITIONS TO DELIVERY OF PUT NOTICES AND CONDITIONS TO CLOSING


Section
7.1               CONDITIONS
PRECEDENT TO THE RIGHT OF THE COMPANY TO ISSUE AND SELL PUT SHARES. The right of the Company to issue and sell the Put Shares
to the Investor is subject to the satisfaction of each of the conditions set forth below:


(a)               
ACCURACY OF INVESTOR’S REPRESENTATIONS
AND WARRANTIES. The representations and warranties of the Investor shall be true and correct in all material respects as of
the Execution Date and as of the date of each Closing as though made at each such time.


(b)               
DELIVERY OF DOCUMENTS. The
Investor shall have executed each of the Transaction Documents and delivered the same to the Company.


(c)               
REGISTRATION STATEMENT. The Company shall
not have the right to issue any Put Shares if, as of the date of the Closing for such issuance and sale, the Registration Statement,
and any amendment or supplement thereto, shall fail to be and remain effective for the resale by the Investor of the Put Shares
and Commitment Shares.


Section
7.2               CONDITIONS
PRECEDENT TO THE OBLIGATION OF INVESTOR TO PURCHASE PUT SHARES. The obligation of the Investor hereunder to purchase Put Shares
is subject to the satisfaction of each of the following conditions:


(a)               
REGISTRATION STATEMENT. The Registration
Statement, and any amendment or supplement thereto, shall be and remain effective for the resale by the Investor of the Put Shares
and the Commitment Shares and (i) neither the Company nor the Investor shall have received notice that the SEC has issued or intends
to issue a stop order with respect to such Registration Statement or that the SEC otherwise has suspended or withdrawn the effectiveness
of such Registration Statement, either temporarily or permanently, or intends or has threatened to do so and (ii) no other suspension
of the use of, or withdrawal of the effectiveness of, such Registration Statement or related prospectus shall exist. The Company
shall have prepared and filed with the SEC a final and complete prospectus (the preliminary form of which shall be included in
the Registration Statement) and shall have delivered to the Investor a true and complete copy thereof. Such prospectus shall be
current and available for the resale by the Investor of all of the Securities covered thereby. 


(b)               
ACCURACY OF THE COMPANY’S REPRESENTATIONS
AND WARRANTIES. The representations and warranties of the Company shall be true and correct in all material respects as of
the Execution Date and as of the date of each Closing (except for representations and warranties under the first sentence of Section
4.3, which are specifically made as of the Execution Date and shall be true and correct in all respects as of the Execution
Date).


(c)               
PERFORMANCE BY THE COMPANY. The Company
shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by
this Agreement to be performed, satisfied or complied with by the Company.


(d)               
NO INJUNCTION. No statute, rule, regulation,
executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or adopted by any court or governmental
authority of competent jurisdiction that prohibits or directly and materially adversely affects any of the transactions contemplated
by the Transaction Documents, and no proceeding shall have been commenced that may have the effect of prohibiting or materially
adversely affecting any of the transactions contemplated by the Transaction Documents.


(e)               
ADVERSE CHANGES. Since the date of filing
of the Company’s most recent SEC Document, no event that had or is reasonably likely to have a Material Adverse Effect has
occurred.


(f)                
NO SUSPENSION OF TRADING IN OR DELISTING OF
COMMON STOCK. The trading of the Common Stock shall not have been suspended by the SEC, the Principal Market or FINRA, or
otherwise halted for any reason, and the Common Stock shall have been approved for listing or quotation on and shall not have
been delisted from the Principal Market. In the event of a suspension, delisting, or halting for any reason, of the trading of
the Common Stock, as contemplated by this Section 7.2(f), the Investor shall have the right to return to the Company any
remaining amount of Put Shares associated with such Option 1 Put or Option 2 Put, and the Option 1 Purchase Price or Option 2
Purchase Price (as applicable) with respect to such Option 1 Put or Option 2 Put shall be reduced accordingly.


(g)               
BENEFICIAL OWNERSHIP LIMITATION. As of
the date of the Closing for such issuance and sale, the number of Put Shares to be purchased by the Investor shall not exceed
the number of such shares that, when aggregated with all other shares of Common Stock then owned by the Investor beneficially
or deemed beneficially owned by the Investor, would result in the Investor owning more than the Beneficial Ownership Limitation
(as defined below), as determined in accordance with Section 16 of the Exchange Act and the regulations promulgated thereunder.
For purposes of this Section 7.2(g), in the event that the amount of Common Stock outstanding, as determined in accordance
with Section 16 of the Exchange Act and the regulations promulgated thereunder, is greater on a Closing Date than on the date
upon which the Put Notice associated with such Closing Date is given, the amount of Common Stock outstanding on such Closing Date
shall govern for purposes of determining whether the Investor, when aggregating all purchases of Common Stock made pursuant to
this Agreement, would own more than the Beneficial Ownership Limitation following such Closing Date. The “Beneficial
Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving
effect to the issuance of shares of Common Stock issuable pursuant to a Put Notice.


(h)               
NO KNOWLEDGE. The Company shall have no
knowledge of any event more likely than not to have the effect of causing the Registration Statement to be suspended or otherwise
ineffective (which event is more likely than not to occur within the fifteen (15) Trading Days following the Trading Day on which
such Put Notice is deemed delivered). The Company shall have no knowledge of any untrue statement (or alleged untrue statement)
of a material fact or omission (or alleged omission) of a material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they were made, not misleading, in the Registration Statement, any
effective registration statement filed pursuant to the Registration Rights Agreement or any post-effective amendment or prospectus
which is a part of the foregoing, unless the Company has filed an amendment with the SEC or taken such other.


(i)                
NO VIOLATION OF SHAREHOLDER APPROVAL REQUIREMENT.
The issuance of the Put Shares shall not violate the shareholder approval requirements of the Principal Market.


(j)                
OFFICER’S CERTIFICATE. On the date
of delivery of each Put Notice, the Investor shall have received the Closing Certificate executed by an executive officer of the
Company and to the effect that all the conditions to such Closing shall have been satisfied as of the date of each such certificate.


(k)               
DWAC ELIGIBLE. The Common Stock must be
DWAC Eligible and not subject to a “DTC chill.”


(l)                
SEC DOCUMENTS. All reports, schedules,
registrations, forms, statements, information and other documents required to have been filed by the Company with the SEC pursuant
to the reporting requirements of the Exchange Act (other than Forms 8-K) shall have been filed with the SEC within the applicable
time periods prescribed for such filings under the Exchange Act.


(m)             
TRANSFER AGENT INSTRUCTION LETTER. The
Transfer Agent Instruction Letter shall have been executed and delivered by the Company to the Transfer Agent and acknowledged
and agreed to in writing by the Transfer Agent, and the Company shall have no knowledge of any fact or circumstance that would
prevent the Transfer Agent from complying with the terms of the Transfer Agent Instruction Letter. 


(n)               
NATIONAL SECURITIES EXCHANGE. The Company’s
Common Stock must be listed on a Principal Market.


(o)               
MINIMUM PRICING. The lowest traded price
of the Common Stock in the five (5) Trading Days immediately preceding the respective Put Date must exceed the Floor Price.


(p)               
NO VIOLATION. No statute, regulation,
order, guidance, decree, writ, ruling or injunction shall have been enacted, entered, promulgated, threatened or endorsed by any
federal, state, local or foreign court or governmental authority of competent jurisdiction, including, without limitation, the
SEC, which prohibits the consummation of or which would materially modify or delay any of the transactions contemplated by the
Transaction Documents.


(q)               
LEGAL OPINION. The Company shall cause
to be delivered to the Investor a written opinion of counsel reasonably satisfactory to the Investor, in form and substance reasonably
satisfactory to the Investor and its counsel, relating to the availability and effectiveness of the Registration Statement, as
supplemented by any prospectus supplement or amendment thereto, and regarding the Company’s compliance with the Delaware
Statutes and the federal securities laws of the United States in the issuance, sale and registration of the Put Shares and Commitment
Shares. 


Article
VIII

LEGENDS


Section
8.1               NO
RESTRICTIVE STOCK LEGEND. No restrictive stock legend shall be placed on the share certificates representing the Put Shares.


Section
8.2               INVESTOR’S
COMPLIANCE. Nothing in this Article VIII shall affect in any way the Investor’s obligations hereunder to comply
with all applicable securities laws upon the sale of the Common Stock.


Article
IX

NOTICES; INDEMNIFICATION


Section
9.1               NOTICES.
All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing
and, unless otherwise specified herein, shall be (a) personally served, (b) deposited in the mail, registered or certified, return
receipt requested, postage prepaid, (c) delivered by reputable air courier service with charges prepaid, or (d) transmitted by
hand delivery, telegram, or e-mail as a PDF, addressed as set forth below or to such other address as such party shall have specified
most recently by written notice given in accordance herewith. Any notice or other communication required or permitted to be given
hereunder shall be deemed effective (i) upon hand delivery or delivery by e-mail at the address designated below (if delivered
on a business day during normal business hours where such notice is to be received), or the first business day following such
delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (ii)
on the second business day following the date of mailing by express courier service or on the fifth business day after deposited
in the mail, in each case, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first
occur.


The
addresses for such communications shall be:


If
to the Company:


NuGenerex
Immuno-Oncology Inc.


10102
USA Today Way


Miramar,
FL 33025


Attention:
Joseph Moscato, CEO


E-mail:
jmoscato@nugenerex.com


Phone:
800-391-6755


 


NuGenerex
Immuno-Oncology Inc.


Anthony
S. Crisci, Esq., CPA


Chief
Legal Officer


E-mail:
acrisci@nugenerex.com


 


With
a copy (which shall not constitute notice) to:


 


Carmel,
Milazzo & Feil LLP


55
West 39th Street, 18th Flr


New
York, NY 10018


Attention:
Jeffrey P. Wofford


E-mail:
jwofford@cmfllp.com


 


If
to the Investor:


Oasis
Capital, LLC


208
Ponce de Leon Ave, Suite 1600


San
Juan, PR 00918


E-mail:
adam@oasis-cap.com


Attention:
Adam Long, Managing Partner


 


with
a copy to (that shall not constitute notice)


Nason,
Yeager, Gerson, Harris & Fumero, P.A.


3001
PGA Boulevard, Suite 305


Palm
Beach Gardens, FL 33410


E-mail:
bbernstein@nasonyeager.com


Attention:
Brian Bernstein, Esq.


Either
party hereto may from time to time change its address or e-mail for notices under this Section 9.1 by giving at least ten
(10) days’ prior written notice of such changed address to the other party hereto.


Section
9.2               INDEMNIFICATION.
Each party hereto (an “Indemnifying Party”) agrees to indemnify and hold harmless the other party along with
its officers, directors, employees, and authorized agents and representatives, and each Person or entity, if any, who controls
such party within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act or the rules and regulations
thereunder (an “Indemnified Party”) from and against any and all Damages, joint or several, and any and all
actions in respect thereof to which the Indemnified Party becomes subject to, resulting from, arising out of or relating to (i)
any misrepresentation, breach of warranty or nonfulfillment of or failure to perform any covenant or agreement on the part of
the Indemnifying Party contained in this Agreement, (ii) any untrue statement or alleged untrue statement of a material fact contained
in the Registration Statement, any registration statement pursuant to the Registration Rights Agreement or any post-effective
amendment thereof or supplement thereto, or the omission or alleged omission therefrom of a material fact required to be stated
therein or necessary to make the statements therein not misleading, (iii) any untrue statement or alleged untrue statement of
a material fact contained in any preliminary prospectus or contained in the final prospectus (as amended or supplemented, if the
Company files any amendment thereof or supplement thereto with the SEC) or the omission or alleged omission to state therein any
material fact necessary to make the statements made therein, in the light of the circumstances under which the statements therein
were made, not misleading, or (iv) any violation or alleged violation by the Company of the Securities Act, the Exchange Act,
any state securities law or any rule or regulation under the Securities Act, the Exchange Act or any state securities law, as
such Damages are incurred, except to the extent such Damages result primarily from the Indemnified Party’s failure to perform
any covenant or agreement contained in this Agreement or the Indemnified Party’s negligence, recklessness, fraud, willful
misconduct or bad faith in performing its obligations under this Agreement; provided, however, that the foregoing
indemnity agreement shall not apply to any Damages of an Indemnified Party to the extent, but only to the extent, arising out
of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made by an Indemnifying Party
in reliance upon and in conformity with written information furnished to the Indemnifying Party by the Indemnified Party expressly
for use in the Registration Statement, any post-effective amendment thereof or supplement thereto, or any preliminary prospectus
or final prospectus (as amended or supplemented).


Section
9.3               METHOD
OF ASSERTING INDEMNIFICATION CLAIMS. All claims for indemnification by any Indemnified Party under Section 9.2 shall
be asserted and resolved as follows:


(a)               
In the event any claim or demand in respect of
which an Indemnified Party might seek indemnity under Section 9.2 is asserted against or sought to be collected from such
Indemnified Party by a Person other than a party hereto or an affiliate thereof (a “Third Party Claim”), the
Indemnified Party shall deliver a written notification, enclosing a copy of all papers served, if any, and specifying the nature
of and basis for such Third Party Claim and for the Indemnified Party’s claim for indemnification that is being asserted
under any provision of Section 9.2 against an Indemnifying Party, together with the amount or, if not then reasonably ascertainable,
the estimated amount, determined in good faith, of such Third Party Claim (a “Claim Notice”) with reasonable
promptness to the Indemnifying Party. If the Indemnified Party fails to provide the Claim Notice with reasonable promptness after
the Indemnified Party receives notice of such Third Party Claim, the Indemnifying Party shall not be obligated to indemnify the
Indemnified Party with respect to such Third Party Claim to the extent that the Indemnifying Party’s ability to defend has
been prejudiced by such failure of the Indemnified Party. The Indemnifying Party shall notify the Indemnified Party as soon as
practicable within the period ending thirty (30) calendar days following receipt by the Indemnifying Party of either a Claim Notice
or an Indemnity Notice (as defined below) (the “Dispute Period”) whether the Indemnifying Party disputes its
liability or the amount of its liability to the Indemnified Party under Section 9.2 and whether the Indemnifying Party
desires, at its sole cost and expense, to defend the Indemnified Party against such Third Party Claim.


(i)                
If the Indemnifying Party notifies the Indemnified
Party within the Dispute Period that the Indemnifying Party desires to defend the Indemnified Party with respect to the Third
Party Claim pursuant to this Section 9.3(a), then the Indemnifying Party shall have the right to defend, with counsel reasonably
satisfactory to the Indemnified Party, at the sole cost and expense of the Indemnifying Party, such Third Party Claim by all appropriate
proceedings, which proceedings shall be vigorously and diligently prosecuted by the Indemnifying Party to a final conclusion or
will be settled at the discretion of the Indemnifying Party (but only with the consent of the Indemnified Party in the case of
any settlement that provides for any relief other than the payment of monetary damages or that provides for the payment of monetary
damages as to which the Indemnified Party shall not be indemnified in full pursuant to Section 9.2). The Indemnifying Party
shall have full control of such defense and proceedings, including any compromise or settlement thereof; provided, however,
that the Indemnified Party may, at the sole cost and expense of the Indemnified Party, at any time prior to the Indemnifying Party’s
delivery of the notice referred to in the first sentence of this clause (i), file any motion, answer or other pleadings or take
any other action that the Indemnified Party reasonably believes to be necessary or appropriate to protect its interests; and provided,
further, that if requested by the Indemnifying Party, the Indemnified Party will, at the sole cost and expense of the Indemnifying
Party, provide reasonable cooperation to the Indemnifying Party in contesting any Third Party Claim that the Indemnifying Party
elects to contest. The Indemnified Party may participate in, but not control, any defense or settlement of any Third Party Claim
controlled by the Indemnifying Party pursuant to this clause (i), and except as provided in the preceding sentence, the Indemnified
Party shall bear its own costs and expenses with respect to such participation. Notwithstanding the foregoing, the Indemnified
Party may takeover the control of the defense or settlement of a Third Party Claim at any time if it irrevocably waives its right
to indemnity under Section 9.2 with respect to such Third Party Claim.


(ii)              
If the Indemnifying Party fails to notify the
Indemnified Party within the Dispute Period that the Indemnifying Party desires to defend the Third Party Claim pursuant to this
Section 9.3(a), or if the Indemnifying Party gives such notice but fails to prosecute vigorously and diligently or settle
the Third Party Claim, or if the Indemnifying Party fails to give any notice whatsoever within the Dispute Period, then the Indemnified
Party shall have the right to defend, at the sole cost and expense of the Indemnifying Party, the Third Party Claim by all appropriate
proceedings, which proceedings shall be prosecuted by the Indemnified Party in a reasonable manner and in good faith or will be
settled at the discretion of the Indemnified Party(with the consent of the Indemnifying Party, which consent will not be unreasonably
withheld). The Indemnified Party will have full control of such defense and proceedings, including any compromise or settlement
thereof; provided, however, that if requested by the Indemnified Party, the Indemnifying Party will, at the sole cost and expense
of the Indemnifying Party, provide reasonable cooperation to the Indemnified Party and its counsel in contesting any Third Party
Claim which the Indemnified Party is contesting. Notwithstanding the foregoing provisions of this clause (ii), if the Indemnifying
Party has notified the Indemnified Party within the Dispute Period that the Indemnifying Party disputes its liability or the amount
of its liability hereunder to the Indemnified Party with respect to such Third Party Claim and if such dispute is resolved in
favor of the Indemnifying Party in the manner provided in clause (iii) below, the Indemnifying Party will not be required to bear
the costs and expenses of the Indemnified Party’s defense pursuant to this clause (ii) or of the Indemnifying Party’s
participation therein at the Indemnified Party’s request, and the Indemnified Party shall reimburse the Indemnifying Party
in full for all reasonable costs and expenses incurred by the Indemnifying Party in connection with such litigation. The Indemnifying
Party may participate in, but not control, any defense or settlement controlled by the Indemnified Party pursuant to this clause
(ii), and the Indemnifying Party shall bear its own costs and expenses with respect to such participation.


(iii)            
If the Indemnifying Party notifies the Indemnified
Party that it does not dispute its liability or the amount of its liability to the Indemnified Party with respect to the Third
Party Claim under Section 9.2 or fails to notify the Indemnified Party within the Dispute Period whether the Indemnifying
Party disputes its liability or the amount of its liability to the Indemnified Party with respect to such Third Party Claim, the
amount of Damages specified in the Claim Notice shall be conclusively deemed a liability of the Indemnifying Party under Section
9.2 and the Indemnifying Party shall pay the amount of such Damages to the Indemnified Party on demand. If the Indemnifying
Party has timely disputed its liability or the amount of its liability with respect to such Third Party Claim, the Indemnifying
Party and the Indemnified Party shall proceed in good faith to negotiate a resolution of such dispute; provided, however,
that if the dispute is not resolved within thirty (30) days after the Claim Notice, the Indemnifying Party shall be entitled to
institute such legal action as it deems appropriate.


(b)               
In the event any Indemnified Party should have
a claim under Section 9.2 against the Indemnifying Party that does not involve a Third Party Claim, the Indemnified Party
shall deliver a written notification of a claim for indemnity under Section 9.2 specifying the nature of and basis for
such claim, together with the amount or, if not then reasonably ascertainable, the estimated amount, determined in good faith,
of such claim (an “Indemnity Notice”) with reasonable promptness to the Indemnifying Party. The failure by
any Indemnified Party to give the Indemnity Notice shall not impair such party’s rights hereunder except to the extent that
the Indemnifying Party demonstrates that it has been irreparably prejudiced thereby. If the Indemnifying Party notifies the Indemnified
Party that it does not dispute the claim or the amount of the claim described in such Indemnity Notice or fails to notify the
Indemnified Party within the Dispute Period whether the Indemnifying Party disputes the claim or the amount of the claim described
in such Indemnity Notice, the amount of Damages specified in the Indemnity Notice will be conclusively deemed a liability of the
Indemnifying Party under Section 9.2 and the Indemnifying Party shall pay the amount of such Damages to the Indemnified
Party on demand. If the Indemnifying Party has timely disputed its liability or the amount of its liability with respect to such
claim, the Indemnifying Party and the Indemnified Party shall proceed in good faith to negotiate a resolution of such dispute;
provided, however, that if the dispute is not resolved within thirty (30) days after the Claim Notice, the Indemnifying Party
shall be entitled to institute such legal action as it deems appropriate.


(c)               
The Indemnifying Party agrees to pay the Indemnified
Party, promptly as such expenses are incurred and are due and payable, for any reasonable legal fees or other reasonable expenses
incurred by them in connection with investigating or defending any such Claim.


(d)               
The indemnity provisions contained herein shall
be in addition to (i) any cause of action or similar rights of the Indemnified Party against the Indemnifying Party or others,
and (ii) any liabilities the Indemnifying Party may be subject to.


Article
X

MISCELLANEOUS


Section
10.1            GOVERNING
LAW. This Agreement shall be governed by and interpreted in accordance with the laws of the State of New York without regard
to the principles of conflicts of law (whether of the State of New York or any other jurisdiction). 


Section
10.2            ARBITRATION.
Any disputes, claims, or controversies arising out of or relating to the Transaction Documents, or the transactions, contemplated
thereby, or the breach, termination, enforcement, interpretation or validity thereof, including the determination of the scope
or applicability of this Agreement to arbitrate, shall be referred to and resolved solely and exclusively by binding arbitration
to be conducted before the Judicial Arbitration and Mediation Service (“JAMS” ), or its successor pursuant
the expedited procedures set forth in the JAMS Comprehensive Arbitration Rules and Procedures (the “Rules”
), including Rules 16.1 and 16.2 of those Rules. The arbitration shall be held in New York, New York, before a tribunal consisting
of three (3) arbitrators each of whom will be selected in accordance with the “strike and rank” methodology set forth
in Rule 15. Either party to this Agreement may, without waiving any remedy under this Agreement, seek from any federal or state
court sitting in the State of New York any interim or provisional relief that is necessary to protect the rights or property of
that party, pending the establishment of the arbitral tribunal. The costs and expenses of such arbitration shall be paid by and
be the sole responsibility of the Company, including but not limited to the Investor’s attorneys’ fees and each arbitrator’s
fees. The arbitrators’ decision must set forth a reasoned basis for any award of damages or finding of liability. The arbitrators’
decision and award will be made and delivered as soon as reasonably possibly and in any case within sixty (60) days’ following
the conclusion of the arbitration hearing and shall be final and binding on the parties and may be entered by any court having
jurisdiction thereof.


Section
10.3            JURY
TRIAL WAIVER. THE COMPANY AND THE INVESTOR HEREBY WAIVE A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT
BY EITHER OF THE PARTIES HERETO AGAINST THE OTHER IN RESPECT OF ANY MATTER ARISING OUT OF OR IN CONNECTION WITH THE TRANSACTION
DOCUMENTS.


Section
10.4            ASSIGNMENT.
This Agreement shall be binding upon and inure to the benefit of the Company and the Investor and their respective successors.
Neither this Agreement nor any rights of the Investor or the Company hereunder may be assigned by either party to any other Person.


Section
10.5            NO
THIRD PARTY BENEFICIARIES. This Agreement is intended for the benefit of the Company and the Investor and their respective
successors, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as set forth
in Article IX.


Section
10.6            TERMINATION.
At any time after the effectiveness of the Registration Statement, the Company shall have the
option to terminate this Agreement for any reason or for no reason by delivering written notice (a “Company Termination
Notice”) to the Investor electing to terminate this Agreement without any liability whatsoever of any party to any other
party under this Agreement (except as set forth below). The Company Termination Notice shall not be effective until one business
day after it has been received by the Investor, provided that this Agreement cannot be terminated (i) while the Investor holds
any Put Shares and (ii) prior to the expiration of the Registration Period (as defined in the Registration Rights Agreement).
In addition, this Agreement shall automatically terminate on the earlier of (i) the end of the Commitment Period; (ii)
the date that the Company sells and the Investor purchases the Maximum Commitment Amount; or (iii) the date in which the Registration
Statement is no longer effective, or (iv) the date that, pursuant to or within the meaning of any Bankruptcy Law, the Company
commences a voluntary case or any Person commences a proceeding against the Company, a Custodian is appointed for the Company
or for all or substantially all of its property or the Company makes a general assignment for the benefit of its creditors. Notwithstanding
the foregoing, in the event of termination of this Agreement, the provisions of Articles III, IV, V, VI, IX and the agreements
and covenants of the Company and the Investor set forth in this Article X shall survive the termination of this Agreement
for the maximum length of time allowed under applicable law.


Section
10.7            ENTIRE
AGREEMENT. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of
the Company and the Investor with respect to the matters covered herein and therein and supersede all prior agreements and understandings,
oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and
schedules.


Section
10.8            FEES
AND EXPENSES. Except as expressly set forth in the Transaction Documents or any other writing to the contrary, each party
shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred
by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall
pay all Transfer Agent fees, stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to
the Investor. The Company shall pay $25,000  to the Investor on the Execution Date
for reimbursement of the Investor’s transaction fees relating to the preparation of the Transaction Documents. 


Section
10.9            COUNTERPARTS.
This Agreement may be executed in multiple counterparts, each of which may be executed by less than all of the parties and shall
be deemed to be an original instrument which shall be enforceable against the parties actually executing such counterparts and
all of which together shall constitute one and the same instrument. This Agreement may be delivered to the other parties hereto
by e-mail of a copy of this Agreement bearing the signature of the parties so delivering this Agreement.


Section
10.10        SEVERABILITY.
In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable
or void, this Agreement shall continue in full force and effect without said provision; provided that such severability shall
be ineffective if it materially changes the economic benefit of this Agreement to any party.


Section
10.11        FURTHER
ASSURANCES. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.


Section
10.12        NO
STRICT CONSTRUCTION. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.


Section
10.13        EQUITABLE
RELIEF. Each party acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the other
by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, each party acknowledges that the remedy
at law for a breach of its obligations under this Agreement will be inadequate and agrees, in the event of a breach or threatened
breach by the such party of the provisions of this Agreement, that the other party shall be entitled, in addition to all other
available remedies at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining,
preventing or curing any breach of this Agreement and to enforce specifically the terms and provisions hereof, without the necessity
of showing economic loss and without any bond or other security being required.


Section
10.14        TITLE
AND SUBTITLES. The titles and subtitles used in this Agreement are used for the convenience of reference and are not to be
considered in construing or interpreting this Agreement.


Section
10.15        AMENDMENTS;
WAIVERS. No provision of this Agreement may be amended or waived by the parties from and after the date that is one (1) Trading
Day immediately preceding the initial filing of the Registration Statement with the SEC. Subject to the immediately preceding
sentence, (i) no provision of this Agreement may be amended other than by a written instrument signed by both parties hereto and
(ii) no provision of this Agreement may be waived other than in a written instrument signed by the party against whom enforcement
of such waiver is sought. No failure or delay in the exercise of any power, right or privilege hereunder shall operate as a waiver
thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof
or of any other right, power or privilege.


Section
10.16        PUBLICITY.
The Company and the Investor shall consult with each other in issuing any press releases or otherwise making public statements
with respect to the transactions contemplated hereby and no party shall issue any such press release or otherwise make any such
public statement, other than as required by law, without the prior written consent of the other parties, which consent shall not
be unreasonably withheld or delayed, except that no prior consent shall be required if such disclosure is required by law, in
which such case the disclosing party shall provide the other party with prior notice of such public statement. Notwithstanding
the foregoing, the Company shall not publicly disclose the name of the Investor without the prior written consent of the Investor,
except to the extent required by law. The Investor acknowledges that this Agreement and all or part of the Transaction Documents
may be deemed to be “material contracts,” as that term is defined by Item 601(b)(10) of Regulation S-K, and that the
Company may therefore be required to file such documents as exhibits to reports or registration statements filed under the Securities
Act or the Exchange Act. The Investor further agrees that the status of such documents and materials as material contracts shall
be determined solely by the Company, in consultation with its counsel.


 


 


**
Signature Page Follows **


 









    	 	1	 



     


    

 


IN
WITNESS WHEREOF, the parties have caused this Agreement to be duly executed by their respective officers thereunto duly authorized
as of the Execution Date.


	 	NUGENEREX IMMUNO-ONCOLOGY INC.
	 	 
	 	By: /s/Joseph Moscato
	 	Name: Joseph Moscato
	 	Title: CEO
	 	 
	 	 
	 	OASIS CAPITAL, LLC
	 	 
	 	By: /s/Adam Long
	 	Name: Adam Long
	 	Title: Managing Partner




 


 


**
Signature Page to Equity Purchase Agreement **


 



    	 	2	 



     


    




EXHIBIT
A


FORM
OF PUT NOTICE


TO:
OASIS CAPITAL, LLC


 


DATE:


We
refer to the Equity Purchase Agreement, dated July _______, 2020 (the “Agreement”), entered into by and between
NuGenerex Immuno-Oncology Inc. and you. Capitalized terms defined in the Agreement shall, unless otherwise defined herein, have
the same meaning when used herein.


We
hereby:


1)Give
you notice that we require you to purchase  Put Shares pursuant to an [ ] Option 1 Put or [ ] Option 2 Put; and


2)
Certify that, as of the date hereof, the conditions set forth in Section 7.2 of the Agreement are
satisfied.


NUGENEREX
IMMUNO-ONCOLOGY INC.


By:


Name:
       


Title:
       









    	 	3	 



     


    




EXHIBIT
B


FORM
OF OFFICER’S CERTIFICATE


OF
NUGENEREX IMMUNO-ONCOLOGY INC.


Pursuant
to Section 7.2(j) of that certain equity purchase agreement, dated July ___, 2020 (the “Agreement”),
by and between NuGenerex Immuno-Oncology Inc. (the “Company”) and Oasis Capital, LLC (the “Investor”),
the undersigned, in his capacity as Chief Financial Officer of the Company, and not in his individual capacity, hereby certifies,
as of the date hereof (such date, the “Condition Satisfaction Date”), the following:


1.       The
representations and warranties of the Company contained in the Agreement are true and correct in all material respects as of the
Condition Satisfaction Date as though made on the Condition Satisfaction Date (except for representations and warranties specifically
made as of a particular date) with respect to all periods, and as to all events and circumstances occurring or existing to and
including the Condition Satisfaction Date, except for any conditions which have temporarily caused any representations or warranties
of the Company set forth in the Agreement to be incorrect and which have been corrected with no continuing impairment to the Company
or the Investor; and


2.       All
of the conditions precedent to the obligation of the Investor to purchase Put Shares set forth in the Agreement, including but
not limited to Section 7.2 of the Agreement, have been satisfied as of the Condition Satisfaction Date.


Capitalized
terms used herein shall have the meanings set forth in the Agreement unless otherwise defined herein.


IN
WITNESS WHEREOF, the undersigned has hereunto affixed his hand as of _________ ___, 2020.


 


By:


Name:


Title:









    	 	4	 



     


    




EXHIBIT
C


FORM
OF TRANSFER AGENT


INSTRUCTION
LETTER


 


 


 


 


 


 









    	 	5	 



     


    

EXHIBIT
D


FORM
OF REGISTRATION RIGHTS AGREEMENT


 


 


 


 









    	 	6	 



     


    




DISCLOSURE
SCHEDULES


 


Schedule
4.10 Registration Rights.


Registration
rights are described in the following SEC Documents:


 


Schedule
4.4 Listing and Maintenance Requirements.


(a) Notices of Non-Compliance


(b) Continued
Compliance






    	 	7